At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
KAN-101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA·interventional·Posted Aug 21, 2023·Updated Dec 18, 2025
In Brief
A Phase 2 clinical trial evaluating KAN-101 and Placebo for Celiac Disease and Coeliac Disease. Completed, enrolled 55 participants across 28 sites in 8 countries.
Detailed Summary
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCeliac Disease, Coeliac Disease
CountriesCanada, Finland, Germany, Ireland, Israel, Netherlands, Poland, United States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
202420252026
First PostedAug 2023
Enrollment StartDec 2023
Primary CompletionJan 2025
Study CompletionJan 2025
TodayJul 2026
First PostedAug 21, 2023
Enrollment StartDec 13, 2023
Primary CompletionJan 3, 2025
Study CompletionJan 13, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.9 years ago
Interventions
KAN-101drug
Dose KAN-101 Intravenous (IV) Infusion
Placebodrug
Placebo Intravenous (IV) Infusion